CVE:VM Voyageur Pharmaceuticals (VM) Stock Price, News & Analysis C$0.17 +0.01 (+3.03%) As of 12:36 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesBuy This Stock About Voyageur Pharmaceuticals Stock (CVE:VM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get VM alerts:Sign Up Key Stats Today's RangeC$0.16▼C$0.1750-Day RangeC$0.16▼C$0.3452-Week RangeC$0.04▼C$0.36Volume264,063 shsAverage Volume203,326 shsMarket CapitalizationC$25.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Voyageur Pharmaceuticals Ltd., together with its subsidiaries, engages in the acquiring, exploring, and developing raw materials for pharmaceutical products, primarily in the province of British Columbia, Canada, and the state of Utah. The company develops barium and iodine-based APIs. The company was formerly known as Voyageur Minerals Ltd. and changed its name to Voyageur Pharmaceuticals Ltd. in December 2019. Voyageur Pharmaceuticals Ltd. was founded in 2017 and is headquartered in Calgary, Canada. Read More Receive VM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Voyageur Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address VM Stock News HeadlinesVoyageur Pharmaceuticals (CVE:VM) Shares Down 2.9% - Should You Sell?August 7, 2025 | americanbankingnews.comVoyageur Pharmaceuticals Launches First Commercial Sale of Barium Contrast AgentsJune 4, 2025 | msn.comElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social Security? What we just discovered in Washington will stun even the most seasoned insiders.August 13 at 2:00 AM | Banyan Hill Publishing (Ad)Voyageur Launches Market Introduction of Barium Contrast Product Line Following Successful Clinical Study ResultsApril 24, 2025 | finance.yahoo.comVoyageur Completes Human Testing of Barium Contrast Products and Prepares for Canadian Market LaunchApril 1, 2025 | finance.yahoo.comVoyageur Pharmaceuticals Ltd.: Voyageur Clarifies Terms of Previously Announced AgreementMarch 3, 2025 | finanznachrichten.deVoyageur Advances MRI Drug Development Using Next Generation Endohedral FullerenesFebruary 18, 2025 | finance.yahoo.comVoyageur Pharmaceuticals With CEO, Brent Willis | February 6th, 2025February 6, 2025 | msn.comSee More Headlines VM Stock Analysis - Frequently Asked Questions How have VM shares performed this year? Voyageur Pharmaceuticals' stock was trading at C$0.09 on January 1st, 2025. Since then, VM shares have increased by 100.0% and is now trading at C$0.17. How do I buy shares of Voyageur Pharmaceuticals? Shares of VM stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Voyageur Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Voyageur Pharmaceuticals investors own include GFG Resources (GFG), Pine Cliff Energy (PNE), Tamarack Valley Energy (TVE), Caladrius Biosciences (CLBS), Capstone Copper (CS), Calibre Mining (CXB) and Mawson Gold (MAW). Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolCVE:VM CIKN/A Webwww.voyageurminerals.ca Phone587-779-6166FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$1.66 million Net MarginsN/A Pretax MarginN/A Return on Equity-117.77% Return on Assets-30.77% Debt Debt-to-Equity Ratio4.23 Current Ratio0.10 Quick Ratio0.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.00 per share Price / Cash Flow35.00 Book ValueC$0.01 per share Price / Book25.09Miscellaneous Outstanding Shares151,517,550Free FloatN/AMarket CapC$25.76 million OptionableNot Optionable Beta0.32 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (CVE:VM) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Voyageur Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Voyageur Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.